Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $41,015.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $82.03, for a total transaction of $41,015.00. Following the completion of the transaction, the vice president owned 77,890 shares in the company, valued at approximately $6,389,316.70. This represents a 0.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Wednesday, May 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $78.16, for a total value of $39,080.00.
• On Monday, April 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $77.95, for a total value of $38,975.00.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $80.52 on Thursday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. ANI Pharmaceuticals, Inc. has a fifty-two week low of $62.60 and a fifty-two week high of $99.50. The stock’s 50-day moving average is $80.12 and its two-hundred day moving average is $79.37. The firm has a market cap of $1.83 billion, a P/E ratio of 20.38 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same period in the prior year, the firm posted $1.70 EPS. The business’s revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts predict that ANI Pharmaceuticals, Inc. will post 8.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ANIP. Arrowstreet Capital Limited Partnership acquired a new position in shares of ANI Pharmaceuticals during the 3rd quarter valued at about $32,992,000. Balyasny Asset Management L.P. grew its stake in ANI Pharmaceuticals by 2,785.7% in the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after buying an additional 276,233 shares during the last quarter. Divisadero Street Capital Management LP acquired a new position in ANI Pharmaceuticals in the 3rd quarter valued at $21,454,000. Rubric Capital Management LP grew its stake in ANI Pharmaceuticals by 354.7% in the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after buying an additional 200,998 shares during the last quarter. Finally, UBS Group AG grew its stake in ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after buying an additional 185,172 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on ANIP. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, June 1st. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.